Integrichain Blog

Blog

340B FAQ Government Pricing
Government Pricing Dave Weiss
October 11, 2021

Frequently Asked Questions: 340B Program

3 Minute Read

The 340B program is subject to increased scrutiny as it continues to grow. We examine common questions about the program and what ICyte solutions are available to identify and...

Capitol Building, where state price transparency laws are enacted

Government Pricing John Whitridge
October 4, 2021

Updates to State Price Transparency Laws

2 Minute Read

As more states begin to adopt price transparency laws, we examine the latest laws enacted by individual states and what it means for manufacturers.

Channel Haley Morgaylo
September 24, 2021

Refined Channel Data: Inventory Analytics

3 Minute Read

How IntegriChain’s Inventory Analytics helps manufacturers conquer the complexity of inventory estimation.

Contracts & Pricing Brendan Crabtree Kevin Ehmann
September 17, 2021

How Discount Cards Are Replacing PBMs

3 Minute Read

We review how discount cards have disrupted the prescription market as well as updates to the most-favored-nation pricing model and new STPR laws in Maine.

Channel Chris Jewell
August 23, 2021

Refined Channel Data: Unblinding

3 Minute Read

Unblinding national datasets gives Life Sciences manufacturers a clear view into where and when their therapies are being utilized.

Contracts & Pricing Ben Fanelli
August 13, 2021

Compliance Guidelines for Government Programs

5 Minute Read

Six key elements to operate an effective compliance program. Also, new VA FSS rules for vaccine drugs, State Price Transparency, and Medicare Part D updates and reminders.

Contracts & Pricing Gourab Khan
July 26, 2021

The Branded Pharma Fee Deadline Approaches

4 Minute Read

We'll tell you how to prepare. Plus new manufacturer awareness for orphan drugs, midnight changes to MDRP, and upholding the ACA.

ICyte Platform Josh Halpern
July 8, 2021

Breaking down the Silos for Next-Generation Access

5 Minute Read

This blog is the fourth in a series that shares our vision for future-proofing Market Access. Manufacturers can evolve the Market Access function to work toward their commercial, financial, and...

Patient Access Josh Halpern
July 1, 2021

Frequently Asked Questions – Data Aggregation 3.0

3 Minute Read

As channels evolve with a shift toward precision medicines, larger patient access obstacles have emerged, and new approaches are needed to transform the world of data aggregation.

Contracts & Pricing Rupal Patel
June 29, 2021

SPTR, CMS Final Rule & VA Public Law Updates

5 Minute Read

The latest regulatory updates and reporting reminders for June 2021.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand